Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia

Blood. 2013 Nov 21;122(22):3694-6. doi: 10.1182/blood-2013-07-516385.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Clone Cells / pathology
  • Dasatinib
  • Female
  • Genes, abl
  • Humans
  • Hydroxyurea / therapeutic use
  • Janus Kinase 2 / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Middle Aged
  • Point Mutation
  • Pyrimidines / therapeutic use
  • Thiazoles / therapeutic use
  • Thrombocythemia, Essential / complications*
  • Thrombocythemia, Essential / drug therapy
  • Thrombocythemia, Essential / genetics*
  • Translocation, Genetic

Substances

  • Pyrimidines
  • Thiazoles
  • JAK2 protein, human
  • Janus Kinase 2
  • Dasatinib
  • Hydroxyurea